The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Baseline profiling to predict response and resistance to CD19 CAR T-cell therapy in B-cell NHL
In this video, Joseph Melenhorst, PhD, Cleveland Clinic, Cleveland, OH, briefly discusses the findings of a decentralized manufacturing study that aimed to identify baseline immune and proteomic features predictive of response and resistance to CD19 CAR T-cell therapy in B-cell non-Hodgkin lymphoma (NHL). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So that abstract is an oral presentation by one of my associates. We did a study to understand if we could identify any baseline features in patients before cells were actually manufactured for CAR T-cells. We analyzed the serum proteomics by Olink, 92 proteins we examined. And we also looked at the T-cell phenotype with a number of panels that we developed in-house, and we discovered that there’s a signature identifiable pre-manufacturing T-cells that predict or actually correlate, predict response to a CD19 targeting 4-1BB co-signaling CAR T-cell...
So that abstract is an oral presentation by one of my associates. We did a study to understand if we could identify any baseline features in patients before cells were actually manufactured for CAR T-cells. We analyzed the serum proteomics by Olink, 92 proteins we examined. And we also looked at the T-cell phenotype with a number of panels that we developed in-house, and we discovered that there’s a signature identifiable pre-manufacturing T-cells that predict or actually correlate, predict response to a CD19 targeting 4-1BB co-signaling CAR T-cell. And those samples were taken from a decentralized manufacturing pipeline. And we validated this set also in a chimeric-type product. So now we can predict with fairly high certainty if a patient would actually respond to a 4-1BB co-signaling CAR. And so the signature entails early memory phenotype with CD127, 27, but also we found that there’s a type 2 signature like we published last year in Nature in ALL. So this is a shared theme among CD19 targeting 4-1BB co-signal CAR T-cells.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
